At a live Case-Based Roundtable event during the 2025 American Society of Hematology (ASH) annual meeting, Joshua Richter, MD, discussed the evolving role of selinexor (Xpovio) in ...
Cemsidomide demonstrated a 50% ORR at 100 μg, with one patient achieving a complete response and no detectable disease. The phase 1 study's dose-escalation phase is complete, and the 100 μg dose is ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — The addition of belantamab mafodotin to pomalidomide and dexamethasone improved outcomes compared with ...
Clinical Trials Arena on MSN
C4 Therapeutics doses first patient in MOMENTUM trial for multiple myeloma
The study will enrol around 100 participants.
What Is Darzalex, and Why Does It Matter? Darzalex Faspro is an injectable medicine used to treat adults with multiple myeloma, a type of blood cancer, and light chain (AL) amyloidosis, a rare ...
Asparaginase treatment is standard in all pediatric acute lymphoblastic leukemia (ALL) regimens, whereas in adults, it is either excluded or administered for a shorter duration. Several adult ALL ...
The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results